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Background: Chronic inflammation has been recognized to foster tumour development. Whether chemotherapy
can be used to neutralize chronic inflammation is unclear.
Methods: We evaluated baseline and nadir neutrophils in 111 patients (pts.) with non-small cell lung cancer (NSCLC)
and 118 pts. with ovarian cancer (OC) treated with chemotherapy administered with dose-individualization to achieve
nadir neutropenia of 1.5. We used predefined baseline neutrophil cut-offs 4.5 × 109/L (NSCLC) and 3.9 × 109/L (OC).
Results: Absence of chemotherapy-induced nadir neutropenia (CTCAE grade 0, neutrophils ≥ LLN) was seen in
23% of OC and 25% of NSCLC pts. Absence of nadir neutropenia was associated with decreased overall survival
(OS) compared with presence (>grade 0) of neutropenia (9 vs. 14 months, P = 0.004 for NSCLC and 23 vs.
56 months; P = 0.01 for OC). Obtaining grade 3/4 neutropenia did not improve survival compared with grade 1/2
neutropenia. In multivariate analyses, baseline neutrophils ≥4.5 × 109/L (HR: 2.0; 95% CI: 1.11-3.44;P = 0.02) and
absence of nadir neutropenia (HR: 1.6; 95% CI: 1.02-2.65;P = 0.04) for NSCLC and absence of nadir neutropenia
(HR: 1.7; 95% CI: 1.04;2.93;P = 0.04) for OC were independently associated with short OS.
Three prognostic neutrophil index (NI) groups were defined. Favourable NI: low baseline neutrophils and presence
of nadir neutropenia (>grade 0), Intermediate NI: elevated baseline neutrophils and presence of nadir neutropenia
(>grade 0), and Poor NI: elevated baseline neutrophils and absence of nadir neutropenia (grade 0). For NSCLC
patients, the median OS was 18.0, 13.4, and 8.8 months for favourable, intermediate and poor NI, respectively
(fav vs. poor P = 0.002; fav vs. intermed P = 0.04; and intermed vs. poor P = 0.03). For OC patients, median OS was
69, 52 and 23 months for favourable, intermediate and poor NI, respectively (fav vs. poor P = 0.03; fav vs.
intermed P = 0.3; and intermed vs. poor P = 0.02). Interestingly, survival rates in the intermediate NI groups
indicated that individualised dose of chemotherapy to induce neutropenia may partly overcome the negative
impact of elevated baseline neutrophils.
Conclusions: A neutrophil index comprising elevated baseline neutrophils and absence of neutropenia
identified a high risk group of NSCLC and ovarian cancer patients with only modest effect of chemotherapy.
New treatment options for this subset of patients are required.
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Although cancer begins as a single cell and initially de-
velops as a clone, by the time a tumour is clinically de-
tectable, it is no longer a mass of isolated, identical,
neoplastic cells [1]. It has been realized that tumours
are composed of an assemblage of cell types that com-
municate and collaborate, including cancer cells, cancer
stem cells, endothelial cells, pericytes, fibroblasts and
tumour-promoting inflammatory cells [2]. Thus, mul-
tiple non-malignant cell types are recruited to become
components of the tumour and contribute to the hall-
marks of cancer [3].
Among inflammatory cells, the realisation of the
negative effect of neutrophils has recently begun to
emerge [4]. Several studies have demonstrated that tu-
mours stimulate neutrophils to promote angiogenesis
and immunosuppression, as well as migration, inva-
sion, and metastasis [5]. In clinical trials, the prognos-
tic role of tumour-infiltrating neutrophils, elevated
blood neutrophils, and elevated blood neutrophil/
lymphocyte ratio has been clearly associated with poor
clinical outcome in several human cancers, most notably
in renal cell carcinoma, melanoma, colorectal cancer, he-
patocellular carcinoma, cholangiocarcinoma, glioblastoma,
GIST, gastric, esophageal, lung, ovarian, head and neck,
and cervical cancer [6-8]. A striking finding is the no-
tion that high baseline neutrophil count hinder benefit
from surgery, chemoradiotherapy, radiofrequency abla-
tion, and chemotherapy [6]. Consequently, neutrophils,
in addition to tumour cells, are potential targets for can-
cer therapy [9,10].
Traditionally, neutropenia in relation to chemother-
apy has been regarded as a harmful side effect that
should be avoided. However, several retrospective stud-
ies have suggested an inferior outcome for patients fail-
ing to achieve mild neutropenia during chemotherapy
for breast, ovarian, and non-small cell lung cancers
(NSCLC) as well as Hodgkin’s lymphoma [11-21] and
for targeted therapy with sunitinib, cetuximab and
imatinib [22-25]. Nevertheless, it is unclear whether
baseline and nadir neutrophils are linked in the individ-
ual patient.
In the present study, we evaluated the prognostic im-
pact of combined baseline and nadir neutrophils in an
institution with a standard practise of individualizing
chemotherapy dosing upwards or downwards to ac-
hieve target nadir neutropenia of 1.5 × 109/L [26,27].
We chose patients with NSCLC and ovarian cancer
(OC) as predefined baseline neutrophil cutoff values of
4.5 × 109/L and 3.9 × 109/L, respectively, have been de-
termined from previous studies [28,29]. We identified a
new prognostic neutrophil index by combining baseline
and nadir neutrophil values in patients with NSCLC
and ovarian cancer.Methods
Patient population
Data from patients diagnosed with non-small cell lung
cancer (stage III-IV) and advanced ovarian cancer (stage
I-IV) treated with chemotherapy between 1997 and 2005
were collected from patient records at the Department
of Medical Oncology at Crown Princess Mary Cancer
Centre Westmead in Sydney Australia.
Eligibility criteria were a complete medical record within
three cycles of chemotherapy and a full set of baseline and
nadir laboratory data. All available medical files were
reviewed and a number of files were excluded due to lack
of essential data. Patients routinely had a nadir blood
count measured 10 to 17 days after chemotherapy or as
appropriate according to schedule. The highest grade of
myelosuppression at nadir was recorded. Demographics,
type of chemotherapy, use of G-CSF, clinical, laboratory,
and survival data were collected. Stage was graded
according to TNM 2002 or FIGO 1998 as appropriate. No
upfront G-CSF was used. Toxicity and laboratory data
were graded according to CTCAE v.3.0. Survival data were
updated May 2010.
The study has received institutional review board and
Ethics Committee approval. (Sydney West Area Health
Service Human Research Ethics Comitee). Since this was
a non-interventional, retrospective, subject-anonymized
study, written patient consent was not required by the
ethics committee.Treatment and toxicity-adjusted dose modification
A protocol of chemotherapy-toxicity adjusted dosing
(CTAD) was implemented as clinical standard practice
in the mid-1990s at the institution [26]. After an initial
administration of chemotherapy based on standard body
surface area, subsequent doses were adjusted upwards or
downwards in each patient to yield target nadir neutrophil
count of 1.5 × 109/L (i.e. CTCAE grade 1 neutropenia). If
target neutropenia was not reached and other haemato-
logical or non-haematological toxicity was ≤Grade 2, the
subsequent dose of chemotherapy was increased by 15-20%.
In contrast, if the patient experienced significant non-
haematological toxicity > Grade 2 toxicity or severe neu-
tropenia, the dose was reduced by 15-20%. Otherwise the
dose remained unchanged [26].Statistical analysis
Summary statistics were performed to estimate relevant
baseline patient demographic and disease characteristics.
Relative chemotherapy intensity was calculated as the
actual cumulated dose of chemotherapy divided by the
standardized cumulated dose according to expected
number of chemotherapy cycles. The impact on out-
come was explored for all patients in each tumour type
Table 1 Patient characteristics for NSCLC patients
(N = 111)
Characteristic N %
Median age, years 61
























Carboplatin based 87 78
Cisplatin based 4 4
Other 20 18
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frequent chemotherapy regimen.
Based on previous studies identifying baseline neutro-
phil count as independent prognostic factors in NSCLC
[28] and ovarian cancer [29] baseline neutrophil counts
were dichotomized according to the pre-defined cutoff
values of 4.5 × 10^9/L for NSCLC and 3.9 × 10^9/L for
ovarian cancer. Patients who developed various CTCAE
version 3 grades of myelosuppression were compared with
those who did not. The relationship between assessed pa-
rameters and overall survival (OS) was evaluated using the
method of Kaplan–Meier and log-rank tests. Multivariate
Cox regression models were constructed to report hazard
ratios (HRs) for OS. Factors with P < 0.1 in univariate ana-
lysis were dichotomized, except for age which was treated
as a continuous variable, and included in the multivariate
model.
For NSCLC patients age, performance status, tumour
stage, presence of bone metastases, baseline haemoglo-
bin level, baseline neutrophil count above the predefined
cut-off, nadir neutropenia grade ≥0, and relative che-
motherapy intensity were included in the multivariate
analysis.
For ovarian cancer patients age, performance status,
FIGO stage, presence of ascites, residual disease, nor-
malisation of CA125, baseline neutrophil count above
the predefined cut-off, and nadir neutropenia grade ≥0
were included in the multivariate analysis.
Differences in baseline neutrophil count in different
tumour stages was compared with either the nonparametric
Mann–Whitney test (NSCLC patients) or Kruskal-Wallis
test (ovarian cancer patients).
All reported P-values were two-tailed; an alpha-value
below 0.05 was considered statistically significant. The
analyses were performed using SPSS version 20.0.0 (IBM
Corporation, NY, USA).Abbreviations: NSCLC non-small-cell lung cancer, ECOG Eastern Cooperative
Oncology Group.Results
A total of 111 patients with non-small cell lung cancer
(NSCLC) and 118 patients with ovarian cancer (OC) ful-
filled inclusion criteria for the present study. Patient
characteristics are shown in Tables 1 and 2. For NSCLC
patients, 71 (64%) achieved ≥ grade 2 nadir neutropenia
(i.e., neutrophils <1.5 × 109/L), 15 (14%) achieved grade
1 nadir neutropenia (i.e., neutrophils < LLN to 1.5 x 109/L),
and 25 (23%) had no chemotherapy-induced neutropenia
(grade 0, i.e., neutrophils ≥ LLN). For ovarian cancer pa-
tients 64 patients (54%) achieved ≥ grade 2 neutropenia, 24
(20%) achieved grade 1 neutropenia, and 30 (25%) had no
neutropenia (grade 0). One ovarian cancer patient received
G-CSF due to neutropenia. Dose increase due to absence
of target neutropenia occurred in 19% of NSCLC and 23%
of OC patients. Dose reduction due to haematological ornon-haematological toxicity occurred in 36% of NSCLC
patients and 25% of OC patients.
Impact of baseline and nadir neutrophils in univariate
analyses
Non-small cell lung cancer
Overall median survival was 13.0 months for NSCLC pa-
tients with a median follow-up of 6.7 years. Patients failing
to achieve any grade of nadir neutropenia (i.e., neutro-
phils ≥ LLN) after chemotherapy had decreased survival
rate compared with patients who obtained any grade of
neutropenia (i.e. >grade 0 neutropenia), median survival 9
vs. 14 months; (P = 0.004). Obtaining grade 3 or 4 neutro-
penia did not improve survival rate compared with grade
1 or 2 neutropenia (Figure 1A).
Table 2 Patient characteristics for ovarian cancer patients
(N = 118)
Characteristic N %
Median age, years 58



























Carbo + Tax 73 62
Carbo monotherapy 33 28
Carbo + other 12 10
Abbreviations: FIGO International Federation of Gynaecology and Obstetrics,
ECOG Eastern Cooperative Oncology Group; CA125 Cancer Antigen 125; Carbo
Carboplatin; Tax Taxol (Paclitaxel).
Figure 1 Kaplan-Meier plot of overall survival for NSCLC patients
(A) (N = 111) and ovarian cancer patients (B) (N = 118) stratified
for neutropenia grade at nadir. Grade 0, neutrophils ≥ LLN;
grade 1, neutrophils < LLN to 1.5 × 109/L; grade 2, <1.5 - 1.0 × 109/L;
grade 3, <1.0 – 0.5 × 109/L; grade 4, < 0.5 × 109/L. P-values obtained
from log-rank test.
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above or equal to the predefined cutoff of 4.5 × 109/L
had decreased OS compared with patients with baseline
neutrophil counts below 4.5, median survival 11.6 vs.
18.0 months; (P = 0.02). The impact of relative dose in-
tensity of chemotherapy was significantly associated with
overall survival (P = 0.003). Other factors associated with
poor overall survival were performance status >0 (P = 0.08),
presence of bone metastases (P = 0.003), Stage IV cancer
(P = 0.001), and haemoglobin count below lower limit of
normal (P = 0.02).We observed a non-significant trend towards higher
median values of baseline neutrophil counts for NSCLC
patients with increasing stage (IIIa vs. IIIB vs. IV; median
5.8, 5.5, and 6.5 × 109/L, respectively; P = 0.13).
Ovarian cancer
Median survival was 50 months for all ovarian cancer pa-
tients with a median follow-up time of 9.0 years. Patients
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grade 0 neutropenia) had less than half the median sur-
vival compared to patients achieving any grade of neutro-
penia (23 vs. 56 months; P = 0.01). Obtaining grade 3 or 4
neutropenia did not improve survival rate compared with
grade 1 or 2 neutropenia (Figure 1B). We observed no
statistically significant survival impact of baseline ele-
vated neutrophils above or below the predefined cutoff
of 3.9x109/L (P = 0.3). Relative chemotherapy dose did
not impact overall survival (HR 1.00; 95% CI 0.98–1.03;
P = 0.6). Other factors significantly associated with poor
overall survival were performance status >0 (P = 0.001),
residual disease >1 cm (P = 0.0001), presence of ascites
(P = 0.0001), and failure to normalize serum CA125
(P = 0.003).
We observed a non-significant trend towards higher
baseline neutrophil counts with increasing FIGO stage
(I, II, III, and IV; median 4.8, 5.3, 5.9, and 7.2 × 109/L,
respectively; P = 0.08).
Multivariate analyses
For NSCLC patients factors independently associated
with short survival in multivariate analysis were failure
to achieve neutropenia with chemotherapy (i.e., grade 0
neutropenia), baseline neutrophil count above or equal
to 4.5 × 109/L, relative chemotherapy intensity <100%, and
TNM stage IV (Table 3).
For ovarian cancer patients the following factors were
independently associated with short survival in multi-
variate analysis: failure to achieve neutropenia with
chemotherapy (i.e., grade 0 neutropenia), minimal re-
sidual disease >1 cm, increasing age, presence of ascites,
and failure to normalize CA125 after chemotherapy
(Table 3).Table 3 Multivariate analysis of association between
on-treatment neutropenia and OS for non-small cell
lung cancer and ovarian cancer
Tumour type HR for death (95% CI) P-value
NSCLC
Neutropenia grade 0 1.6 (1.02;2.65) 0.04
Baseline neutrophils ≥ 4.5 2.0 (1.11;3.44) 0.02
Stage IV cancer 1.8 (1.18;2.71) 0.006
Relative chemo intensity < 100% 1.7 (1.11;2.60) 0.01
Ovarian cancer
Neutropenia grade 0 1.7 (1.04;2.93) 0.04
Residual disease > 1 cm 2.9 (1.73;4.81) 0.0001
Age at diagnosis 1.02 (1.00;1.05) 0.04
Ascites present 2.2 (1.11;4.23) 0.02
CA125 not normalized 3.2 (1.75;6.00) 0.0001
Factors with multivariate significance level <0.05 are shown.
Abbreviations: OS overall survival; NSCLC Non-Small Cell Lung Cancer; Grade 0
neutropenia at nadir ≥ 2.0 × 10^9/L; CA125 Cancer antigen 125.Impact of baseline and nadir neutrophil index
To evaluate the combined prognostic impact of both
baseline and nadir neutrophils we performed a four-
group analyses. Based on predefined baseline neutrophil
cutoff values and nadir neutropenia grade (0 vs. >0), we
identified a favourable neutrophil index prognostic group
(comprising patients with low baseline neutrophils and
presence (>grade 0) of nadir neutropenia), an intermedi-
ate neutrophil index prognostic group (comprising pa-
tients with elevated baseline neutrophils and presence
(>grade 0) of nadir neutropenia), and a poor neutrophil
index prognostic group (comprising patients with ele-
vated baseline neutrophils and absence of (grade 0)
nadir neutropenia). The fourth potential group of low
baseline neutrophils and grade 0 nadir neutropenia
comprised only 4 patients with ovarian cancer and no
NSCLC patients, and was therefore not classified. For
NSCLC patients, the median OS was 18.0, 13.4, and
8.8 months for favourable, intermediate and poor neu-
trophil index prognostic group, respectively (Figure 2A):
(favourable vs. poor P = 0.002, favourable vs. intermedi-
ate P = 0.04, intermediate vs. poor P = 0.03). Number of
dose increase and dose reduction in the intermediate
group was not statistically different from the poor prog-
nostic group. For ovarian cancer patients, median OS
was 69, 52 and 23 months for favourable, intermediate
and poor neutrophil index prognostic group, respectively
(Figure 2B): favourable vs. poor P = 0.03, favourable vs.
intermediate P = 0.3, intermediate vs. poor P = 0.02. A sig-
nificantly higher number of patients in the intermediate
group had dose reduction compared with the poor
prognostic group (P = 0.017) whereas no difference in
dose increase or relative chemotherapy dose intensity
was observed between the intermediate and poor prog-
nostic group.
Discussion
To our knowledge, this is the first study to identify a prog-
nostic neutrophil index in non-small cell lung cancer
(NSCLC) and ovarian cancer patients taking into account
both pre-treatment and post-treatment neutrophils. Using
baseline and nadir neutrophils in a combined prognostic
index we were able to identify a subgroup of patients -
with baseline neutrophils above the pre-defined cutoffs
and failure to achieve neutropenia following chemother-
apy - who had a dismal prognosis comprising approxi-
mately one quarter of the patient population. In this poor
neutrophil index group it appears that chemotherapy had
minimal impact for resolution or neutralization of the
negative effect of neutrophils despite the use of a protocol
designed to induce neutropenia. It is unknown whether
further dose escalation in those individuals would have
had a positive benefit. It might be that the effect of
chemotherapy in these patients has reached its ceiling and
Figure 2 Kaplan-Meier plot of overall survival for NSCLC
patients (A) (N = 111) and ovarian cancer patients (B) (N = 118)
stratified for favourable neutrophil index (NI) (low baseline
neutrophils and presence of nadir neutropenia), intermediate
neutrophil index (elevated baseline neutrophils and presence of
nadir neutropenia), and poor neutrophil index (elevated
baseline neutrophils and absence of nadir neutropenia)
prognostic group. A fourth group with low baseline neutrophils
and absence of nadir neutropenia comprised only 4 patients with
ovarian cancer and no NSCLC, and was not classified.
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tients with baseline neutrophils below the pre-defined cut-
off and who obtained neutropenia below lover limit ofnormal (>grade 0) did benefit from chemotherapy and
had a two to three-fold better overall survival.
High baseline neutrophil count hinder benefit from
surgery, chemoradiotherapy, radiofrequency ablation,
and chemotherapy in several human cancers (reviewed
in [6]). Our findings validate the cutoff baseline neutro-
phil count above or equal to 4.5 × 109/L in NSCLC pa-
tients previously identified by Teramukai et al. [28] as
an independent prognostic factor for poor outcome.
Other studies in NSCLC have also demonstrated an ad-
verse prognostic effect of high baseline neutrophil count
[30-34]. Data from the Teramukai study also suggested a
link between high pre-treatment neutrophil count and
increased treatment-related non-haematological toxicity.
The incidence of grade 3 or 4 non-haematological tox-
icity within the first three cycles of treatment was signifi-
cantly higher in the high-neutrophil group compared to
the low neutrophil group. Moreover, none of the pa-
tients in the high-neutrophil group who experienced
grade 3 or 4 non-haematological toxicity within the first
three cycles completed the planned six cycles [28]. This
data suggests that simply increasing the dose of chemo-
therapy to induce neutropenia may be difficult to
achieve in those patients with a high neutrophil count.
However, it should be noted that in the study by
Teramukai, 47% of patients had elevated baseline neu-
trophil count above 4.5, whereas in our study we had
81% of patients with elevated baseline neutrophil count
above 4.5. This means that we have a higher proportion
of patients in our study with poor prognostic features.
Nonetheless, we were able to demonstrate benefit from
chemotherapy in a group of patients.
High neutrophil count has been shown to be negative
prognositc factor for other tumour types. In colorectal
cancer patients treated with anti-VEGF containing regi-
mens, elevated neutrophil count predicted poor OS and
RFS [35]. In gastrointestinal stromal tumours (GIST) el-
evated baseline neutrophil count correlated with initial
as well as late resistance to imatinib treatment [36]. In
metastatic renal cell carcinoma, elevated baseline blood
neutrophil count has been integrated as a validated
prognostic factor in the Heng criteria for patients treated
with targeted therapy [37] and both elevated blood neu-
trophils as well as presence of intratumoural neutrophils
were independently correlated with poor survival in pa-
tients treated with cytokines [38]. Taken together, elevated
neutrophils have serious clinical implications. However,
we were unable to confirm the cutoff baseline neutrophils
count above 3.9 × 109/L in ovarian cancer patients identi-
fied by Banerjee et al. [29], probable due to small sample
size in our series.
Treatment-induced neutropenia was found to be an
independent favourable variable in our population. Ap-
proximately one quarter of the patients failed to achieve
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adjusted protocol, where the goal was to induce neutro-
penia, and these patients had a worse survival. Moreover,
we observed that severe neutropenia (i.e., grade 3–4) was
no better than mild neutropenia (i.e., grade 1–2) but
that both were better than no neutropenia (i.e., grade 0)
in terms of improved median survival. In other words,
it is the presence, but not the severity, of neutropeniaTable 4 Drugs targeting inflammatory immune cells in the tu
haematological cancers)
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NCT00169104 G-CSF Sustained neut
NCT00014456 G-CSF
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NCT00043394 Promune TLR9 agon
NCT00070642 Promune TLR9 agon
NCT00043407 Promune TLR9 agon
NCT00292045 Promune TLR9 agon
NCT00669292 Promune TLR9 agon
Multiple Vaccines (Multiple targets) T-cell activa
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[13] and Kishida et al. [15] have previously shown an
inferior survival in NSCLC patients who experienced
no treatment-related neutropenia (grade 0) but that
no apparent additional benefit was seen with higher
than grade 1 neutropenia. If validated prospectively,
these findings may impact future routine clinical
practice.mour microenvironment of solid tumours (excluding
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have practical implications, is that among patients with
higher baseline neutrophils, approximately 75% obtained
neutropenia > grade 0 following chemotherapy and sub-
sequently had a significantly improved overall survival
compared to those 25% who experienced no neutropenia.
These figures were almost identical in NSCLC and OC pa-
tients. Similar assessments have been done in colorectal
cancer using neutrophil/lymphocyte ratio (NLR) as a
marker [39]. Baseline blood NLR (>5) was shown to inde-
pendently predict poor OS. Importantly, normalization of
the NLR after one cycle of chemotherapy was observed in
a subset of patients, which resulted in a 2-month PFS im-
provement (5.8 vs. 3.7 months) compared with patients
without NLR normalization [39]. However, normalization
of the NLR after one cycle of chemotherapy did not result
in a statistically significant improvement in OS compared
with patients without NLR normalization. No chemother-
apy dose individualization was done in these patients
based on toxicity or nadir neutrophil count, as was done
in our study. Thus, these data imply that not all patients
with elevated baseline neutrophil are “protected from the
benefits of chemotherapy” as suggested by Maione et al.
[40]. In our series both the higher baseline count and
absence of treatment-induced neutropenia were inde-
pendent adverse prognostic factors and thus were not
linked. Moreover, the relative dose intensity of che-
motherapy was an independent prognostic factor in
NSCLC. This implies that the dose of chemotherapy
matters and may partially overcome the negative effects
of an elevated baseline neutrophil count. The results in
our intermediate prognosis group patients in both cancer
groups seem to support this concept. Patients with a rela-
tively high baseline neutrophil count who developed neutro-
penia from chemotherapy (i.e., the intermediate prognostic
group) had a statistically significantly better survival than
those patients who did not achieve treatment-induced neu-
tropenia (i.e., the poor prognostic group). However, survival
was still lower compared to patients with relatively low
neutrophil count at baseline (i.e., the favorable group).
Inflammatory cells, including neutrophils, influence
many aspects of cancer initiation, progression and meta-
static potential in the tumour microenvironment [41].
Recruitment of neutrophils from the bone marrow to
sites of inflammation is a well-documented process guided
by chemochine-, lipid-, complement- and N-formylated
peptide chemoattractant mediators [5]. However, human
studies evaluating at the same point in time peripheral
blood inflammatory cells and intratumoural inflammatory
cells are scarce. Recently, in resected stage I-IIIA NSCLC
patients [8] we demonstrated densities of tumour-associated
CD66+ neutrophils and CD163+ macrophages were cor-
related with adverse clinical prognostic factors as well as
CRP and white blood cell (WBC) systemic inflammatorymarkers. We also demonstrated that elevated blood CRP
and WBC were associated with short recurrence free
interval (RFS) and overall survival but tumour-associated
neutrophils and macrophages were not directly correlated
with RFS or overall survival [8]. In patients with metastatic
renal cell carcinoma, elevated blood neutrophils as well as
presence of CD66b+ intratumoural neutrophils were inde-
pendently correlated with poor OS in multivariate analysis
[38]. This suggests that the tumour microenvironment
may have two compartments, a local and a systemic and
that both compartments may be important targets for ther-
apy. Assessment of chemotherapy for resolution of chronic
inflammation is a new paradigm and should be evaluated
further in randomized trials incorporating the neutrophil
index in the study design. Targeting chronic inflammation
in the tumour microenvironment is an area of intense re-
search. In Table 4 we have outlined drugs approved or in
clinical trials that target inflammatory immune cells.
Further research in the area of chronic inflammation
and cancer is encouraged.
Limitations of our study are the low sample size, the
retrospective design, inhomogeneous chemotherapy reg-
imens, and patient accrual over a long period of time.
Additionally, the requirement for data for three cycles of
treatment excludes patients who died early, potentially
skewing the survival analysis. However, the present study
was conducted in two independent, different tumour
types with achievement of almost identical results.
Conclusions
In conclusion, absence of chemotherapy-induced neutro-
penia was an independent adverse prognostic factor in
NSCLC and ovarian cancer patients. By combining base-
line elevated neutrophil count and absence of neutropenia,
we identified a poor prognostic group who appeared to
have little benefit from chemotherapy despite a dose escal-
ation protocol. New treatment options for this subset of
patients are required. Importantly, we found an intermedi-
ate prognostic group where the induction of neutropenia
by chemotherapy may have partially overcome the nega-
tive impact of elevated baseline neutrophils leading to a
better survival. This has implications for dose individualisa-
tion in this subgroup. The combined prognostic neutrophil
index comprising both baseline and nadir neutrophil count
is a potentially new and important finding that requires val-
idation in larger, prospective studies.
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